GP-2250 + Gemcitabine for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, GP-2250, combined with gemcitabine for patients with advanced pancreatic cancer who haven't responded to other treatments. The goal is to see if this combination works better than existing options. Gemcitabine has been widely used in the treatment of advanced pancreatic cancer, often in combination with other drugs to improve results.
Who Is on the Research Team?
Anup Kasi, MD
Principal Investigator
University of Kansas
Are You a Good Fit for This Trial?
Adults over 18 with advanced pancreatic cancer that's unremovable or has spread, and who've had certain previous chemotherapies can join. They need a measurable tumor, good blood counts, organ function, and must use effective birth control. Exclusions include recent other cancers (except some skin/breast/cervical), heart disease, lung conditions, major surgery within the last month, or COVID-19 recently.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Monotherapy
GP-2250 is administered as a single-dose monotherapy during Cycle 1
Combination Therapy
Participants receive GP-2250 in combination with gemcitabine in subsequent cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- GP-2250
Find a Clinic Near You
Who Is Running the Clinical Trial?
Geistlich Pharma AG
Lead Sponsor
Translational Drug Development
Collaborator